Gene therapy, gene targeting and induced pluripotent stem cells: Applications in monogenic disease treatment

Biotechnology Advances

Volumn 28, Issue 6, 2010, Pages 715-724

  Wong, Gabriel Kun Yung ^a   Chiu, Andrew T ^a  

^a HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

Author keywords

Gene targeting; Gene therapy; Induced pluripotent stem cells; Monogenic diseases; Reprogramming; Zinc finger nucleases

Indexed keywords

CYTOLOGY; DISEASE CONTROL; DISEASES; GENETIC ENGINEERING; METALS; PROTEINS; STEM CELLS;

DISEASE TREATMENT; GENE TARGETING; GENETIC APPROACH; GENETIC MATERIALS; HOMOLOGOUS RECOMBINATION; INDUCED PLURIPOTENT STEM CELLS; REPROGRAMMING; ZINC FINGER NUCLEASE;

GENE THERAPY;

DISEASE TREATMENT; GENE; GENETIC ANALYSIS; MUTATION; PROTEIN; RECOMBINATION;

EID: 77957017768     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biotechadv.2010.05.019     Document Type: Review

References (177)

1. Aasen T., Raya A., Barrero M.J., Garreta E., Consiglio A., Gonzalez F., et al. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat Biotechnol 2008, 26:1276-1284.
2. Amabile G., Meissner A. Induced pluripotent stem cells: current progress and potential for regenerative medicine. Trends Mol Med 2009, 15:59-68.
3. Amberger J., Bocchini C.A., Scott A.F., Hamosh A. McKusick's Online Mendelian Inheritance in Man (OMIM). Nucleic Acids Res 2009, 37:D793-D796.
4. Aoi T., Yae K., Nakagawa M., Ichisaka T., Okita K., Takahashi K., et al. Generation of pluripotent stem cells from adult mouse liver and stomach cells. Science 2008, 321:699-702.
5. Bank A. Regulation of human fetal hemoglobin: new players, new complexities. Blood 2006, 107:435-443.
6. Bass A.J., Watanabe H., Mermel C.H., Yu S., Perner S., Verhaak R.G., et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 2009, 41:1238-1242.
7. Bell P., Moscioni A.D., Mccarter R.J., Wu D., Gao G., Hoang A., et al. Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver. Mol Ther 2006, 14:34-44.
8. Bernstein K.A., Rothstein R. At loose ends: resecting a double-strand break. Cell 2009, 137:807-810.
9. Bruscia E., Sangiuolo F., Sinibaldi P., Goncz K.K., Novelli G., Gruenert D.C. Isolation of CF cell lines corrected at DeltaF508-CFTR locus by SFHR-mediated targeting. Gene Ther 2002, 9:683-685.
10. Cai J., Li W., Su H., Qin D., Yang J., Zhu F., et al. Generation of human induced pluripotent stem cells from umbilical cord matrix and amniotic membrane mesenchymal cells. J Biol Chem 2010, 285:11227-11234. (Electronic publication ahead of print 2010 Feb 5).
11. Capecchi M.R. Altering the genome by homologous recombination. Science 1989, 244:1288-1292.
12. Capecchi M.R. The new mouse genetics: altering the genome by gene targeting. Trends Genet 1989, 5:70-76.
13. Capecchi M.R. Generating mice with targeted mutations. Nat Med 2001, 7:1086-1090.
14. Carey B.W., Markoulaki S., Hanna J., Saha K., Gao Q., Mitalipova M., et al. Reprogramming of murine and human somatic cells using a single polycistronic vector. Proc Natl Acad Sci U S A 2009, 106:157-162.
15. Cathomen T., Joung J.K. Zinc-finger nucleases: the next generation emerges. Mol Ther 2008, 16:1200-1207.
16. Cavazzana-Calvo M., Hacein-Bey S., de Saint Basile G., Gross F., Yvon E., Nusbaum P., et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000, 288:669-672.
17. Chamberlain J.R., Schwarze U., Wang P.R., Hirata R.K., Hankenson K.D., Pace J.M., et al. Gene targeting in stem cells from individuals with osteogenesis imperfecta. Science 2004, 303:1198-1201.
18. Chang C.W., Lai Y.S., Pawlik K.M., Liu K., Sun C.W., Li C., et al. Polycistronic lentiviral vector for "hit and run" reprogramming of adult skin fibroblasts to induced pluripotent stem cells. Stem Cells 2009, 27:1042-1049.
19. Conrad S., Renninger M., Hennenlotter J., Wiesner T., Just L., Bonin M., et al. Generation of pluripotent stem cells from adult human testis. Nature 2008, 456:344-349.
20. Costa M., Dottori M., Sourris K., Jamshidi P., Hatzistavrou T., Davis R., et al. A method for genetic modification of human embryonic stem cells using electroporation. Nat Protoc 2007, 2:792-796.
21. Davis R.P., Ng E.S., Costa M., Mossman A.K., Sourris K., Elefanty A.G., et al. Targeting a GFP reporter gene to the MIXL1 locus of human embryonic stem cells identifies human primitive streak-like cells and enables isolation of primitive hematopoietic precursors. Blood 2008, 111:1876-1884.
22. de Montalembert M. Management of sickle cell disease. BMJ 2008, 337:a1397.
23. Di Domenico A.I., Christodoulou I., Pells S.C., McWhir J., Thomson A.J. Sequential genetic modification of the hprt locus in human ESCs combining gene targeting and recombinase-mediated cassette exchange. Cloning Stem Cells 2008, 10:217-230.
24. Dimos J.T., Rodolfa K.T., Niakan K.K., Weisenthal L.M., Mitsumoto H., Chung W., et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008, 321:1218-1221.
25. Donsante A., Vogler C., Muzyczka N., Crawford J.M., Barker J., Flotte T., et al. Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. Gene Ther 2001, 8:1343-1346.
26. Donsante A., Miller D.G., Li Y., Vogler C., Brunt E.M., Russell D.W., et al. AAV vector integration sites in mouse hepatocellular carcinoma. Science 2007, 317:477.
27. Duinsbergen D., Salvatori D., Eriksson M., Mikkers H. Tumors originating from induced pluripotent stem cells and methods for their prevention. Ann N Y Acad Sci 2009, 1176:197-204.
28. Duncan A., Hadlaczky G. Chromosomal engineering. Curr Opin Biotechnol 2007, 18:420-424.
29. Durai S., Mani M., Kandavelou K., Wu J., Porteus M.H., Chandrasegaran S. Zinc finger nucleases: custom-designed molecular scissors for genome engineering of plant and mammalian cells. Nucleic Acids Res 2005, 33:5978-5990.
30. Ebert A.D., Yu J., Rose F.F., Mattis V.B., Lorson C.L., Thomson J.A., et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009, 457:277-280.
31. Eminli S., Foudi A., Stadtfeld M., Maherali N., Ahfeldt T., Mostoslavsky G., et al. Differentiation stage determines potential of hematopoietic cells for reprogramming into induced pluripotent stem cells. Nat Genet 2009, 41:968-976.
32. Foster K.W., Ren S., Louro I.D., Lobo-Ruppert S.M., Mckie-Bell P., Grizzle W., et al. Oncogene expression cloning by retroviral transduction of adenovirus E1A-immortalized rat kidney RK3E cells: transformation of a host with epithelial features by c-MYC and the zinc finger protein GKLF. Cell Growth Differ 1999, 10:423-434.
33. Foster K.W., Frost A.R., McKie-Bell P., Lin C.Y., Engler J.A., Grizzle W.E., et al. Increase of GKLF messenger RNA and protein expression during progression of breast cancer. Cancer Res 2000, 60:6488-6495.
34. Gidekel S., Pizov G., Bergman Y., Pikarsky E. Oct-3/4 is a dose-dependent oncogenic fate determinant. Cancer Cell 2003, 4:361-370.
35. Goncz K.K., Colosimo A., Dallapiccola B., Gagne L., Hong K., Novelli G., et al. Expression of DeltaF508 CFTR in normal mouse lung after site-specific modification of CFTR sequences by SFHR. Gene Ther 2001, 8:961-965.
36. Goncz K.K., Prokopishyn N.L., Abdolmohammadi A., Bedayat B., Maurisse R., Davis B.R., et al. Small fragment homologous replacement-mediated modification of genomic beta-globin sequences in human hematopoietic stem/progenitor cells. Oligonucleotides 2006, 16:213-224.
37. Gonzalez F., Barragan Monasterio M., Tiscornia G., Montserrat Pulido N., Vassena R., Batlle Morera L., et al. Generation of mouse-induced pluripotent stem cells by transient expression of a single nonviral polycistronic vector. Proc Natl Acad Sci U S A 2009, 106:8918-8922.
38. Hacein-Bey-Abina S., Von Kalle C., Schmidt M., McCormack M.P., Wulffraat N., Leboulch P., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302:415-419.
39. Hacein-Bey-Abina S., Garrigue A., Wang G.P., Soulier J., Lim A., Morillon E., et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008, 118:3132-3142.
40. Hanna J., Wernig M., Markoulaki S., Sun C.W., Meissner A., Cassady J.P., et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007, 318:1920-1923.
41. Harper S.Q. Progress and challenges in RNA interference therapy for Huntington disease. Arch Neurol 2009, 66:933-938.
42. Hatada S., Nikkuni K., Bentley S.A., Kirby S., Smithies O. Gene correction in hematopoietic progenitor cells by homologous recombination. Proc Natl Acad Sci U S A 2000, 97:13807-13811.
43. Hatada S., Arnold L.W., Hatada T., Cowhig J.E., Ciavatta D., Smithies O. Isolating gene-corrected stem cells without drug selection. Proc Natl Acad Sci U S A 2005, 102:16357-16361.
44. Hochedlinger K., Yamada Y., Beard C., Jaenisch R. Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell 2005, 121:465-477.
45. Hockemeyer D., Soldner F., Beard C., Gao Q., Mitalipova M., Dekelver R.C., et al. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat Biotechnol 2009, 27:851-857.
46. Huangfu D., Maehr R., Guo W., Eijkelenboom A., Snitow M., Chen A.E., et al. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol 2008, 26:795-797.
47. Huangfu D., Osafune K., Maehr R., Guo W., Eijkelenboom A., Chen S., et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol 2008, 26:1269-1275.
48. Ichida J.K., Blanchard J., Lam K., Son E.Y., Chung J.E., Egli D., et al. A small-molecule inhibitor of tgf-Beta signaling replaces sox2 in reprogramming by inducing nanog. Cell Stem Cell 2009, 5:491-503.
49. Imarisio S., Carmichael J., Korolchuk V., Chen C.W., Saiki S., Rose C., et al. Huntington's disease: from pathology and genetics to potential therapies. Biochem J 2008, 412:191-209.
50. Irion S., Luche H., Gadue P., Fehling H.J., Kennedy M., Keller G. Identification and targeting of the ROSA26 locus in human embryonic stem cells. Nat Biotechnol 2007, 25:1477-1482.
51. Jaenisch R., Young R. Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming. Cell 2008, 132:567-582.
52. Jasin M. Genetic manipulation of genomes with rare-cutting endonucleases. Trends Genet 1996, 12:224-228.
53. Jeter C.R., Badeaux M., Choy G., Chandra D., Patrawala L., Liu C., et al. Functional evidence that the self-renewal gene NANOG regulates human tumor development. Stem Cells 2009, 27:993-1005.
54. Jia F., Wilson K.D., Sun N., Gupta D.M., Huang M., Li Z., et al. A nonviral minicircle vector for deriving human iPS cells. Nat Methods 2010, 7:197-199.
55. Judson R.L., Babiarz J.E., Venere M., Blelloch R. Embryonic stem cell-specific microRNAs promote induced pluripotency. Nat Biotechnol 2009, 27:459-461.
56. Jung S.C., Han I.P., Limaye A., Xu R., Gelderman M.P., Zerfas P., et al. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice. Proc Natl Acad Sci U S A 2001, 98:2676-2681.
57. Kaji K., Norrby K., Paca A., Mileikovsky M., Mohseni P., Woltjen K. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 2009, 458:771-775.
58. Kazuki Y., Hiratsuka M., Takiguchi M., Osaki M., Kajitani N., Hoshiya H., et al. Complete genetic correction of ips cells from Duchenne muscular dystrophy. Mol Ther 2010, 18:386-393.
59. Kim H.J., Lee H.J., Kim H., Cho S.W., Kim J.S. Targeted genome editing in human cells with zinc finger nucleases constructed via modular assembly. Genome Res 2009, 19:1279-1288.
60. Kim J.B., Zaehres H., Wu G., Gentile L., Ko K., Sebastiano V., et al. Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors. Nature 2008, 454:646-650.
61. Kim J.B., Sebastiano V., Wu G., Arauzo-Bravo M.J., Sasse P., Gentile L., et al. Oct4-induced pluripotency in adult neural stem cells. Cell 2009, 136:411-419.
62. Kim J.S., Pabo C.O. Getting a handhold on DNA: design of poly-zinc finger proteins with femtomolar dissociation constants. Proc Natl Acad Sci U S A 1998, 95:2812-2817.
63. Knowles M.R., Hohneker K.W., Zhou Z., Olsen J.C., Noah T.L., Hu P.C., et al. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N Engl J Med 1995, 333:823-831.
64. Kumar S., Chanda D., Ponnazhagan S. Therapeutic potential of genetically modified mesenchymal stem cells. Gene Ther 2008, 15:711-715.
65. Lavigne M.D., Yates L., Coxhead P., Gorecki D.C. Nuclear-targeted chimeric vector enhancing nonviral gene transfer into skeletal muscle of Fabry mice in vivo. FASEB J 2008, 22:2097-2107.
66. Le Provost F., Lillico S., Passet B., Young R., Whitelaw B., Vilotte J.L. Zinc finger nuclease technology heralds a new era in mammalian transgenesis. Trends Biotechnol 2010, 28:134-141.
67. Lee G., Papapetrou E.P., Kim H., Chambers S.M., Tomishima M.J., Fasano C.A., et al. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature 2009, 461:402-406.
68. Levasseur D.N., Ryan T.M., Pawlik K.M., Townes T.M. Correction of a mouse model of sickle cell disease: lentiviral/antisickling beta-globin gene transduction of unmobilized, purified hematopoietic stem cells. Blood 2003, 102:4312-4319.
69. Liang S.B., Yoshimitsu M., Poeppl A., Rasaiah V.I., Cai J., Fowler D.H., et al. Multiple reduced-intensity conditioning regimens facilitate correction of Fabry mice after transplantation of transduced cells. Mol Ther 2007, 15:618-627.
70. Lin T., Ambasudhan R., Yuan X., Li W., Hilcove S., Abujarour R., et al. A chemical platform for improved induction of human iPSCs. Nat Methods 2009, 6:805-808.
71. Liu Q., Segal D.J., Ghiara J.B., Barbas C.F. Design of polydactyl zinc-finger proteins for unique addressing within complex genomes. Proc Natl Acad Sci U S A 1997, 94:5525-5530.
72. Lowry W.E., Richter L., Yachechko R., Pyle A.D., Tchieu J., Sridharan R., et al. Generation of human induced pluripotent stem cells from dermal fibroblasts. Proc Natl Acad Sci U S A 2008, 105:2883-2888.
73. Lyssiotis C.A., Foreman R.K., Staerk J., Garcia M., Mathur D., Markoulaki S., et al. Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf4. Proc Natl Acad Sci U S A 2009, 106:8912-8917.
74. Macnab S., Whitehouse A. Progress and prospects: human artificial chromosomes. Gene Ther 2009, 16:1180-1188.
75. Maeder M.L., Thibodeau-Beganny S., Osiak A., Wright D.A., Anthony R.M., Eichtinger M., et al. Rapid "open-source" engineering of customized zinc-finger nucleases for highly efficient gene modification. Mol Cell 2008, 31:294-301.
76. Maherali N., Ahfeldt T., Rigamonti A., Utikal J., Cowan C., Hochedlinger K. A high-efficiency system for the generation and study of human induced pluripotent stem cells. Cell Stem Cell 2008, 3:340-345.
77. Marcaida M.J., Munoz I.G., Blanco F.J., Prieto J., Montoya G. Homing endonucleases: from basics to therapeutic applications. Cell Mol Life Sci 2010, 67:727-748.
78. Marson A., Foreman R., Chevalier B., Bilodeau S., Kahn M., Young R.A., et al. Wnt signaling promotes reprogramming of somatic cells to pluripotency. Cell Stem Cell 2008, 3:132-135.
79. Medin J.A., Tudor M., Simovitch R., Quirk J.M., Jacobson S., Murray G.J., et al. Correction in trans for Fabry disease: expression, secretion and uptake of alpha-galactosidase A in patient-derived cells driven by a high-titer recombinant retroviral vector. Proc Natl Acad Sci U S A 1996, 93:7917-7922.
80. Meissner A., Wernig M., Jaenisch R. Direct reprogramming of genetically unmodified fibroblasts into pluripotent stem cells. Nat Biotechnol 2007, 25:1177-1181.
81. Meyer N., Penn L.Z. Reflecting on 25years with MYC. Nat Rev Cancer 2008, 8:976-990.
82. Miller D.G., Rutledge E.A., Russell D.W. Chromosomal effects of adeno-associated virus vector integration. Nat Genet 2002, 30:147-148.
83. Miller D.G., Trobridge G.D., Petek L.M., Jacobs M.A., Kaul R., Russell D.W. Large-scale analysis of adeno-associated virus vector integration sites in normal human cells. J Virol 2005, 79:11434-11442.
84. Miller J.C., Holmes M.C., Wang J., Guschin D.Y., Lee Y.L., Rupniewski I., et al. An improved zinc-finger nuclease architecture for highly specific genome editing. Nat Biotechnol 2007, 25:778-785.
85. Mitsui K., Suzuki K., Aizawa E., Kawase E., Suemori H., Nakatsuji N., et al. Gene targeting in human pluripotent stem cells with adeno-associated virus vectors. Biochem Biophys Res Commun 2009, 388:711-717.
86. Mittelman D., Moye C., Morton J., Sykoudis K., Lin Y., Carroll D., et al. Zinc-finger directed double-strand breaks within CAG repeat tracts promote repeat instability in human cells. Proc Natl Acad Sci U S A 2009, 106:9607-9612.
87. Miyoshi N., Ishii H., Nagai K., Hoshino H., Mimori K., Tanaka F., et al. Defined factors induce reprogramming of gastrointestinal cancer cells. Proc Natl Acad Sci U S A 2010, 107:40-45.
88. Montier T., Delepine P., Pichon C., Ferec C., Porteous D.J., Midoux P. Non-viral vectors in cystic fibrosis gene therapy: progress and challenges. Trends Biotechnol 2004, 22:586-592.
89. Nakai H., Wu X., Fuess S., Storm T.A., Munroe D., Montini E., et al. Large-scale molecular characterization of adeno-associated virus vector integration in mouse liver. J Virol 2005, 79:3606-3614.
90. Nelson T.J., Martinez-Fernandez A., Yamada S., Perez-Terzic C., Ikeda Y., Terzic A. Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells. Circulation 2009, 120:408-416.
91. Nishimura K., Nakagawa T., Ono K., Ogita H., Sakamoto T., Yamamoto N., et al. Transplantation of mouse induced pluripotent stem cells into the cochlea. NeuroReport 2009, 20:1250-1254.
92. Novo F.J., Gorecki D.C., Goldspink G., Macdermot K.D. Gene transfer and expression of human alpha-galactosidase from mouse muscle in vitro and in vivo. Gene Ther 1997, 4:488-492.
93. O'Connor T.P., Crystal R.G. Genetic medicines: treatment strategies for hereditary disorders. Nat Rev Genet 2006, 7:261-276.
94. Oh I.H., Fabry M.E., Humphries R.K., Pawliuk R., Leboulch P., Hoffman R., et al. Expression of an anti-sickling beta-globin in human erythroblasts derived from retrovirally transduced primitive normal and sickle cell disease hematopoietic cells. Exp Hematol 2004, 32:461-469.
95. Okabe M., Otsu M., Ahn D.H., Kobayashi T., Morita Y., Wakiyama Y., et al. Definitive proof for direct reprogramming of hematopoietic cells to pluripotency. Blood 2009, 114:1764-1767.
96. Okada Y., Ueshin Y., Hasuwa H., Takumi K., Okabe M., Ikawa M. Targeted gene modification in mouse ES cells using integrase-defective lentiviral vectors. Genesis 2009, 47:217-223.
97. Okita K., Ichisaka T., Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 2007, 448:313-317.
98. Okita K., Nakagawa M., Hyenjong H., Ichisaka T., Yamanaka S. Generation of mouse induced pluripotent stem cells without viral vectors. Science 2008, 322:949-953.
99. O'Sullivan B.P., Freedman S.D. Cystic fibrosis. Lancet 2009, 373:1891-1904.
100. Paiboonsukwong K., Ohbayashi F., Shiiba H., Aizawa E., Yamashita T., Mitani K. Correction of mutant Fanconi anemia gene by homologous recombination in human hematopoietic cells using adeno-associated virus vector. J Gene Med 2009, 11:1012-1019.
101. Pandya A.Y., Talley L.I., Frost A.R., Fitzgerald T.J., Trivedi V., Chakravarthy M., et al. Nuclear localization of KLF4 is associated with an aggressive phenotype in early-stage breast cancer. Clin Cancer Res 2004, 10:2709-2719.
102. Park J., Murray G.J., Limaye A., Quirk J.M., Gelderman M.P., Brady R.O., et al. Long-term correction of globotriaosylceramide storage in Fabry mice by recombinant adeno-associated virus-mediated gene transfer. Proc Natl Acad Sci U S A 2003, 100:3450-3454.
103. Park I.H., Arora N., Huo H., Maherali N., Ahfeldt T., Shimamura A., et al. Disease-specific induced pluripotent stem cells. Cell 2008, 134:877-886.
104. Park I.H., Zhao R., West J.A., Yabuuchi A., Huo H., Ince T.A., et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008, 451:141-146.
105. Pavletich N.P., Pabo C.O. Zinc finger-DNA recognition: crystal structure of a Zif268-DNA complex at 2.1 A. Science 1991, 252:809-817.
106. Pawliuk R., Westerman K.A., Fabry M.E., Payen E., Tighe R., Bouhassira E.E., et al. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science 2001, 294:2368-2371.
107. Perumbeti A., Higashimoto T., Urbinati F., Franco R., Meiselman H.J., Witte D., et al. A novel human gamma-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: critical determinants for successful correction. Blood 2009, 114:1174-1185.
108. Porteus M.H., Carroll D. Gene targeting using zinc finger nucleases. Nat Biotechnol 2005, 23:967-973.
109. Pruett-Miller S.M., Connelly J.P., Maeder M.L., Joung J.K., Porteus M.H. Comparison of zinc finger nucleases for use in gene targeting in mammalian cells. Mol Ther 2008, 16:707-717.
110. Pruett-Miller S.M., Reading D.W., Porter S.N., Porteus M.H. Attenuation of zinc finger nuclease toxicity by small-molecule regulation of protein levels. PLoS Genet 2009, 5:e1000376.
111. Przybylska M., Wu I.H., Zhao H., Ziegler R.J., Tousignant J.D., Desnick R.J., et al. Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors. J Gene Med 2004, 6:85-92.
112. Qin G., Takenaka T., Telsch K., Kelley L., Howard T., Levade T., et al. Preselective gene therapy for Fabry disease. Proc Natl Acad Sci U S A 2001, 98:3428-3433.
113. Radecke S., Radecke F., Cathomen T., Schwarz K. Zinc-finger Nuclease-induced Gene Repair With Oligodeoxynucleotides: Wanted and Unwanted Target Locus Modifications. Mol Ther 2010, 18:743-753.
114. Ramalho-Santos M. iPS cells: insights into basic biology. Cell 2009, 138:616-618.
115. Raper S.E., Chirmule N., Lee F.S., Wivel N.A., Bagg A., Gao G.P., et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003, 80:148-158.
116. Raya A., Rodriguez-Piza I., Guenechea G., Vassena R., Navarro S., Barrero M.J., et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature 2009, 460:53-59.
117. Rideout W.M., Hochedlinger K., Kyba M., Daley G.Q., Jaenisch R. Correction of a genetic defect by nuclear transplantation and combined cell and gene therapy. Cell 2002, 109:17-27.
118. Ruby K.M., Zheng B. Gene targeting in a HUES line of human embryonic stem cells via electroporation. Stem Cells 2009, 27:1496-1506.
119. Russell D.W., Hirata R.K. Human gene targeting by viral vectors. Nat Genet 1998, 18:325-330.
120. Samakoglu S., Lisowski L., Budak-Alpdogan T., Usachenko Y., Acuto S., Di Marzo R., et al. A genetic strategy to treat sickle cell anemia by coregulating globin transgene expression and RNA interference. Nat Biotechnol 2006, 24:89-94.
121. Sangiuolo F., Bruscia E., Serafino A., Nardone A.M., Bonifazi E., Lais M., et al. In vitro correction of cystic fibrosis epithelial cell lines by small fragment homologous replacement (SFHR) technique. BMC Med Genet 2002, 3:8.
122. Schierling B., Noel A.J., Wende W., Hien le T., Volkov E., Kubareva E., et al. Controlling the enzymatic activity of a restriction enzyme by light. Proc Natl Acad Sci U S A 2010, 107:1361-1366.
123. Schultz B.R., Chamberlain J.S. Recombinant adeno-associated virus transduction and integration. Mol Ther 2008, 16:1189-1199.
124. Sedivy J.M., Dutriaux A. Gene targeting and somatic cell genetics - a rebirth or a coming of age?. Trends Genet 1999, 15:88-90.
125. Shi Y., Desponts C., Do J.T., Hahm H.S., Scholer H.R., Ding S. Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds. Cell Stem Cell 2008, 3:568-574.
126. Shi Y., Do J.T., Desponts C., Hahm H.S., Scholer H.R., Ding S. A combined chemical and genetic approach for the generation of induced pluripotent stem cells. Cell Stem Cell 2008, 2:525-528.
127. Smithies O. Forty years with homologous recombination. Nat Med 2001, 7:1083-1086.
128. Soldner F., Hockemeyer D., Beard C., Gao Q., Bell G.W., Cook E.G., et al. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 2009, 136:964-977.
129. Somia N., Verma I.M. Gene therapy: trials and tribulations. Nat Rev Genet 2000, 1:91-99.
130. Sommer C.A., Stadtfeld M., Murphy G.J., Hochedlinger K., Kotton D.N., Mostoslavsky G. Induced pluripotent stem cell generation using a single lentiviral stem cell cassette. Stem Cells 2009, 27:543-549.
131. Sonoda E., Hochegger H., Saberi A., Taniguchi Y., Takeda S. Differential usage of non-homologous end-joining and homologous recombination in double strand break repair. DNA Repair (Amst) 2006, 5:1021-1029.
132. Stadtfeld M., Brennand K., Hochedlinger K. Reprogramming of pancreatic beta cells into induced pluripotent stem cells. Curr Biol 2008, 18:890-894.
133. Stadtfeld M., Nagaya M., Utikal J., Weir G., Hochedlinger K. Induced pluripotent stem cells generated without viral integration. Science 2008, 322:945-949.
134. Steinberg M.H., Rodgers G.P. Pharmacologic modulation of fetal hemoglobin. Medicine (Baltimore) 2001, 80:328-344.
135. Stuart M.J., Nagel R.L. Sickle-cell disease. Lancet 2004, 364:1343-1360.
136. Sugimoto Y., Aksentijevich I., Murray G.J., Brady R.O., Pastan I., Gottesman M.M. Retroviral coexpression of a multidrug resistance gene (MDR1) and human alpha-galactosidase A for gene therapy of Fabry disease. Hum Gene Ther 1995, 6:905-915.
137. Sun N., Panetta N.J., Gupta D.M., Wilson K.D., Lee A., Jia F., et al. Feeder-free derivation of induced pluripotent stem cells from adult human adipose stem cells. Proc Natl Acad Sci U S A 2009, 106:15720-15725.
138. Sun N., Longaker M.T., Wu J.C. Human iPS cell-based therapy: Considerations before clinical applications. Cell Cycle 2010, 9.
139. Suzuki K., Mitsui K., Aizawa E., Hasegawa K., Kawase E., Yamagishi T., et al. Highly efficient transient gene expression and gene targeting in primate embryonic stem cells with helper-dependent adenoviral vectors. Proc Natl Acad Sci U S A 2008, 105:13781-13786.
140. Szczepek M., Brondani V., Buchel J., Serrano L., Segal D.J., Cathomen T. Structure-based redesign of the dimerization interface reduces the toxicity of zinc-finger nucleases. Nat Biotechnol 2007, 25:786-793.
141. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
142. Takahashi H., Hirai Y., Migita M., Seino Y., Fukuda Y., Sakuraba H., et al. Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer. Proc Natl Acad Sci U S A 2002, 99:13777-13782.
143. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
144. Takenaka T., Hendrickson C.S., Tworek D.M., Tudor M., Schiffmann R., Brady R.O., et al. Enzymatic and functional correction along with long-term enzyme secretion from transduced bone marrow hematopoietic stem/progenitor and stromal cells derived from patients with Fabry disease. Exp Hematol 1999, 27:1149-1159.
145. Takenaka T., Murray G.J., Qin G., Quirk J.M., Ohshima T., Qasba P., et al. Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells. Proc Natl Acad Sci U S A 2000, 97:7515-7520.
146. Thomson J.A., Itskovitz-Eldor J., Shapiro S.S., Waknitz M.A., Swiergiel J.J., Marshall V.S., et al. Embryonic stem cell lines derived from human blastocysts. Science 1998, 282:1145-1147.
147. Tsai S.Y., Clavel C., Kim S., Ang Y.S., Grisanti L., Lee D.F., et al. Oct4 and klf4 reprogram dermal papilla cells into induced pluripotent stem cells. Stem Cells 2010, 28:221-228.
148. Urbach A., Schuldiner M., Benvenisty N. Modeling for Lesch-Nyhan disease by gene targeting in human embryonic stem cells. Stem Cells 2004, 22:635-641.
149. Utikal J., Maherali N., Kulalert W., Hochedlinger K. Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells. J Cell Sci 2009, 122:3502-3510.
150. Vandendriessche T., Ivics Z., Izsvak Z., Chuah M.K. Emerging potential of transposons for gene therapy and generation of induced pluripotent stem cells. Blood 2009, 114:1461-1468.
151. Viswanathan S.R., Powers J.T., Einhorn W., Hoshida Y., Ng T.L., Toffanin S., et al. Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet 2009, 41:843-848.
152. Wah D.A., Bitinaite J., Schildkraut I., Aggarwal A.K. Structure of FokI has implications for DNA cleavage. Proc Natl Acad Sci U S A 1998, 95:10564-10569.
153. Wang Y., Jiang Y., Liu S., Sun X., Gao S. Generation of induced pluripotent stem cells from human beta-thalassemia fibroblast cells. Cell Res 2009, 19:1120-1123.
154. Wernig M., Lengner C.J., Hanna J., Lodato M.A., Steine E., Foreman R., et al. A drug-inducible transgenic system for direct reprogramming of multiple somatic cell types. Nat Biotechnol 2008, 26:916-924.
155. Wernig M., Zhao J.P., Pruszak J., Hedlund E., Fu D., Soldner F., et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci U S A 2008, 105:5856-5861.
156. Wilmut I. The first direct reprogramming of adult human fibroblasts. Cell Stem Cell 2007, 1:593-594.
157. Wilson J.M. Medicine. A history lesson for stem cells. Science 2009, 324:727-728.
158. Woltjen K., Michael I.P., Mohseni P., Desai R., Mileikovsky M., Hamalainen R., et al. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 2009, 458:766-770.
159. Wu L.C., Sun C.W., Ryan T.M., Pawlik K.M., Ren J., Townes T.M. Correction of sickle cell disease by homologous recombination in embryonic stem cells. Blood 2006, 108:1183-1188.
160. Xu D., Alipio Z., Fink L.M., Adcock D.M., Yang J., Ward D.C., et al. Phenotypic correction of murine hemophilia A using an iPS cell-based therapy. Proc Natl Acad Sci U S A 2009, 106:808-813.
161. Yakubov E., Rechavi G., Rozenblatt S., Givol D. Reprogramming of human fibroblasts to pluripotent stem cells using mRNA of four transcription factors. Biochem Biophys Res Commun 2010, 394:189-193.
162. Yamanaka S. A fresh look at iPS cells. Cell 2009, 137:13-17.
163. Yang Y., Nunes F.A., Berencsi K., Furth E.E., Gonczol E., Wilson J.M. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A 1994, 91:4407-4411.
164. Ye L., Chang J.C., Lin C., Sun X., Yu J., Kan Y.W. Induced pluripotent stem cells offer new approach to therapy in thalassemia and sickle cell anemia and option in prenatal diagnosis in genetic diseases. Proc Natl Acad Sci U S A 2009, 106:9826-9830.
165. Yoshida Y., Takahashi K., Okita K., Ichisaka T., Yamanaka S. Hypoxia enhances the generation of induced pluripotent stem cells. Cell Stem Cell 2009, 5:237-241.
166. Yoshimitsu M., Sato T., Tao K., Walia J.S., Rasaiah V.I., Sleep G.T., et al. Bioluminescent imaging of a marking transgene and correction of Fabry mice by neonatal injection of recombinant lentiviral vectors. Proc Natl Acad Sci U S A 2004, 101:16909-16914.
167. Yoshimitsu M., Higuchi K., Dawood F., Rasaiah V.I., Ayach B., Chen M., et al. Correction of cardiac abnormalities in fabry mice by direct intraventricular injection of a recombinant lentiviral vector that engineers expression of alpha-galactosidase A. Circ J 2006, 70:1503-1508.
168. Yoshimitsu M., Higuchi K., Ramsubir S., Nonaka T., Rasaiah V.I., Siatskas C., et al. Efficient correction of Fabry mice and patient cells mediated by lentiviral transduction of hematopoietic stem/progenitor cells. Gene Ther 2007, 14:256-265.
169. Yu J., Vodyanik M.A., Smuga-Otto K., Antosiewicz-Bourget J., Frane J.L., Tian S., et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318:1917-1920.
170. Yu J., Hu K., Smuga-Otto K., Tian S., Stewart R., Slukvin I.I., et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science 2009, 324:797-801.
171. Zarate Y.A., Hopkin R.J. Fabry's disease. Lancet 2008, 372:1427-1435.
172. Zhou H., Wu S., Joo J.Y., Zhu S., Han D.W., Lin T., et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 2009, 4:381-384.
173. Ziegler R.J., Yew N.S., Li C., Cherry M., Berthelette P., Romanczuk H., et al. Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer. Hum Gene Ther 1999, 10:1667-1682.
174. Ziegler R.J., Lonning S.M., Armentano D., Li C., Souza D.W., Cherry M., et al. AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry mice. Mol Ther 2004, 9:231-240.
175. Ziegler R.J., Cherry M., Barbon C.M., Li C., Bercury S.D., Armentano D., et al. Correction of the biochemical and functional deficits in fabry mice following AAV8-mediated hepatic expression of alpha-galactosidase A. Mol Ther 2007, 15:492-500.
176. Zou J., Maeder M.L., Mali P., Pruett-Miller S.M., Thibodeau-Beganny S., Chou B.K., et al. Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. Cell Stem Cell 2009, 5:97-110.
177. Zwaka T.P., Thomson J.A. Homologous recombination in human embryonic stem cells. Nat Biotechnol 2003, 21:319-321.